Shaw and Hoffmann to receive SCCT 2018 Gold Medal Award
Friday, July 6, 2018
Posted by: Claire Johns
The Society of Cardiovascular Computed Tomography (SCCT) will present it’s 2018 Gold Medal Award to Leslee J. Shaw, PhD, FSCCT, and Udo Hoffmann, MD, MPH, at the SCCT 13th Annual Scientific Meeting, July 12 – 15 in Dallas, Texas. The SCCT Gold Medal Award recognizes outstanding leaders who have made landmark contributions to the field of cardiovascular computed tomography and to the Society.
“Drs. Shaw and Hoffmann represent the best in our field, and we are thrilled to recognize both with the Gold Medal Award — the highest honor bestowed by SCCT,” says SCCT President Todd C. Villines, MD, FSCCT. “They each exemplify outstanding leadership through their lifetime commitment to clinical excellence, research and education.”
Shaw, who served as SCCT president from 2016 to 2017, is professor of health services research in radiology at Weill Cornell Medical College. She is an outcomes research scientist with a background in the diagnosis of coronary disease and in the evaluation of cardiovascular imaging modalities. Shaw has more than 600 publications and presented more than 300 talks in major scientific meetings around the world. Among her notable achievements is her research focused on novel clinical management strategies, comparative effectiveness studies, and economic analysis of the financial burden of cardiovascular illness that uniquely affects diverse racial and ethnic groups of women and men.
Hoffmann is professor of radiology at Harvard Medical School and serves as director of the Cardiac MR PET CT Program at Massachusetts General Hospital, where he leads a multidisciplinary group focused on using advanced imaging to improve prevention, diagnosis and treatment of the disease. He is also the director of a National Heart, Lung, and Blood Institute T32 program in cardiac imaging, and has trained more than 100 researchers and clinicians. His significant accomplishments include leading landmark clinical trials in cardiovascular imaging such as ROMICAT I and II, PROMISE and REPRIEVE, as well as leading computed tomography imaging in the Framingham Heart Study.